Marinomed Biotech AG, located in Korneuburg, Austria, reported a significant cybercrime incident on April 2, 2025. The company revealed that approximately EUR 677,000 had been transferred to third parties outside the European Economic Area, marking a substantial financial loss. Despite immediate attempts to reverse the transfer or block the funds at the recipient bank, these efforts were unsuccessful. As a result, the company is facing a serious financial setback, though the Management Board has assured that the company’s liquidity remains secured for the time being.
In response to the cybercrime, Marinomed Biotech has filed criminal charges with the relevant investigating authorities.
The company is actively collaborating with external advisors and security experts to fully investigate the breach and identify the perpetrators. The company has also initiated an internal review to determine whether its insurance policies can cover the damages caused by the loss of funds.
These efforts are critical in addressing the financial and operational implications of the cyberattack.
While Marinomed Biotech has not yet been able to recover the stolen funds, it remains determined to resolve the situation. The company is continuing to engage with law enforcement to track the movement of the stolen money and hold the responsible parties accountable.
In the meantime, the company is reassessing its internal processes and strengthening its cybersecurity measures to prevent future attacks. Marinomed is also working on improving its financial safeguards to ensure the protection of its assets and minimize risks in the future.
This incident underscores the growing threat of cybercrime in the biotechnology sector, with companies like Marinomed Biotech now vulnerable to attacks targeting their financial systems.
Reference:
